Evaluación de la validez de las funciones SCORE de bajo riesgo y calibrada para población española en las cohortes FRESCO / Validity assessment of low-risk SCORE function and SCORE function calibrated to the Spanish population in the FRESCO cohorts

Introducción y objetivos. Estudiar la validez de la función SCORE original de bajo riesgo sin y con colesterol unido a lipoproteínas de alta densidad y SCORE calibrada en población española. Métodos. Análisis agrupado con datos individuales de 12 estudios de cohorte de base poblacional. Se incluyó a 30.919 participantes de 40-64 años sin enfermedades cardiovasculares en el momento del reclutamiento, que se siguieron durante 10 años para la mortalidad cardiovascular contemplada en el proyecto SCORE. La validez de las funciones se analizó mediante el área bajo la curva ROC (discriminación) y el test de Hosmer-Lemeshow (calibración), respectivamente. Resultados. Se dispuso de 286.105 personas/año. La mortalidad a 10 años por causas cardiovasculares fue del 0,6%. La razón de casos esperados/observados fue de 9,1, 6,5 y 9,1 en varones y de 3,3, 1,3 y 1,9 en mujeres con las funciones SCORE original de bajo riesgo sin y con colesterol unido a lipoproteínas de alta densidad y SCORE calibrada, respectivamente; diferencias estadísticamente significativas con el test de calibración de Hosmer-Lemeshow entre la mortalidad predicha con SCORE y la observada (p < 0,001 en ambos sexos y en todas las funciones). Las áreas bajo la curva ROC con SCORE original fueron 0,68 en varones y 0,69 en mujeres. Conclusiones. Todas las versiones de las funciones SCORE disponibles en España sobreestiman significativamente la mortalidad cardiovascular observada en la población española. A pesar de la aceptable capacidad de discriminación, la predicción del número de acontecimientos cardiovasculares mortales (calibración) fue significativamente imprecisa (AU)

Introduction and objectives. To assess the validity of the original low-risk SCORE function without and with high-density lipoprotein cholesterol and SCORE calibrated to the Spanish population. Methods. Pooled analysis with individual data from 12 Spanish population-based cohort studies. We included 30 919 individuals aged 40 to 64 years with no history of cardiovascular disease at baseline, who were followed up for 10 years for the causes of death included in the SCORE project. The validity of the risk functions was analyzed with the area under the ROC curve (discrimination) and the Hosmer-Lemeshow test (calibration), respectively. Results. Follow-up comprised 286 105 persons/y. Ten-year cardiovascular mortality was 0.6%. The ratio between estimated/observed cases ranged from 9.1, 6.5, and 9.1 in men and 3.3, 1.3, and 1.9 in women with original low-risk SCORE risk function without and with high-density lipoprotein cholesterol and calibrated SCORE, respectively; differences were statistically significant with the Hosmer-Lemeshow test between predicted and observed mortality with SCORE (P < .001 in both sexes and with all functions). The area under the ROC curve with the original SCORE was 0.68 in men and 0.69 in women. Conclusions. All versions of the SCORE functions available in Spain significantly overestimate the cardiovascular mortality observed in the Spanish population. Despite the acceptable discrimination capacity, prediction of the number of fatal cardiovascular events (calibration) was significantly inaccurate (AU)

Validity Assessment of Low-risk SCORE Function and SCORE Function Calibrated to the Spanish Population in the FRESCO Cohorts.

INTRODUCTION AND OBJECTIVES: To assess the validity of the original low-risk SCORE function without and with high-density lipoprotein cholesterol and SCORE calibrated to the Spanish population. METHODS: Pooled analysis with individual data from 12 Spanish population-based cohort studies. We included 30 919 individuals aged 40 to 64 years with no history of cardiovascular disease at baseline, who were followed up for 10 years for the causes of death included in the SCORE project. The validity of the risk functions was analyzed with the area under the ROC curve (discrimination) and the Hosmer-Lemeshow test (calibration), respectively. RESULTS: Follow-up comprised 286 105 persons/y. Ten-year cardiovascular mortality was 0.6%. The ratio between estimated/observed cases ranged from 9.1, 6.5, and 9.1 in men and 3.3, 1.3, and 1.9 in women with original low-risk SCORE risk function without and with high-density lipoprotein cholesterol and calibrated SCORE, respectively; differences were statistically significant with the Hosmer-Lemeshow test between predicted and observed mortality with SCORE (P < .001 in both sexes and with all functions). The area under the ROC curve with the original SCORE was 0.68 in men and 0.69 in women. CONCLUSIONS: All versions of the SCORE functions available in Spain significantly overestimate the cardiovascular mortality observed in the Spanish population. Despite the acceptable discrimination capacity, prediction of the number of fatal cardiovascular events (calibration) was significantly inaccurate.

Interaction between cardiovascular risk factors and body mass index and 10-year incidence of cardiovascular disease, cancer death, and overall mortality.

The effect of above-normal body mass index (BMI) on health outcomes is controversial because it is difficult to distinguish from the effect due to BMI-associated cardiovascular risk factors. The objective was to analyze the impact on 10-year incidence of cardiovascular disease, cancer deaths and overall mortality of the interaction between cardiovascular risk factors and BMI. We conducted a pooled analysis of individual data from 12 Spanish population cohorts with 10-year follow-up. Participants had no previous history of cardiovascular diseases and were 35-79years old at basal examination. Body mass index was measured at baseline being the outcome measures ten-year cardiovascular disease, cancer and overall mortality. Multivariable analyses were adjusted for potential confounders, considering the significant interactions with cardiovascular risk factors. We included 54,446 individuals (46.5% with overweight and 27.8% with obesity). After considering the significant interactions, the 10-year risk of cardiovascular disease was significantly increased in women with overweight and obesity [Hazard Ratio=2.34 (95% confidence interval: 1.19-4.61) and 5.65 (1.54-20.73), respectively]. Overweight and obesity significantly increased the risk of cancer death in women [3.98 (1.53-10.37) and 11.61 (1.93-69.72)]. Finally, obese men had an increased risk of cancer death and overall mortality [1.62 (1.03-2.54) and 1.34 (1.01-1.76), respectively]. In conclusion, overweight and obesity significantly increased the risk of cancer death and of fatal and non-fatal cardiovascular disease in women; whereas obese men had a significantly higher risk of death for all causes and for cancer. Cardiovascular risk factors may act as effect modifiers in these associations.

Grasa epicárdica en la población general de mediana edad y su asociación con el síndrome metabólico / Epicardial adipose tissue in the general middle-aged population and its association with metabolic syndrome

Introducción y objetivos: Actualmente hay cada vez más interés en el tejido adiposo epicárdico (TAE) como marcador de enfermedad cardiovascular. Nuestro objetivo es describir el TAE medido por ecocardiograma, y determinar su asociación con el síndrome metabólico (SM), dentro del estudio poblacional RIVANA. Métodos: Se incluyó a 880 sujetos de 45 a 74 años (492 con SM según la definición armonizada). Se realizó una exploración física y se tomó una muestra sanguínea para obtener el perfil bioquímico. Se midió el espesor del TAE con ecocardiografía transtorácica al final de la sístole. Resultados: Entre los sujetos sin SM, la prevalencia de TAE ≥ 5 mm aumentaba significativamente con la edad (> 65 frente a 45-54 años, OR = 8,22; IC95%, 3,90-17,35; p lineal < 0,001). El TAE se asoció significativamente con el SM (5.o frente a 1.er quintil, OR = 3,26; IC95%, 1,59-6,71; p lineal = 0,001). Respecto a los criterios individuales, el TAE se asoció independientemente con los criterios colesterol unido a lipoproteínas de alta densidad bajo (5.o frente a 1.er quintil, OR = 2,65; IC95%, 1,16-6,05; p lineal = 0,028), triglicéridos altos (5.o frente a 1.er quintil, OR = 2,22; IC95%, 1,26-3,90; p lineal = 0,003) y elevado perímetro abdominal (5.o frente a 1.er quintil, OR = 6,85; IC95%, 2,91-16,11; p lineal < 0,001). Conclusiones En una submuestra de la población general, la grasa epicárdica aumentó significativa e independientemente con la edad, y su incremento se asoció independientemente con el SM, el colesterol unido a lipoproteínas de alta densidad bajo, los triglicéridos altos y un elevado perímetro abdominal (AU)

Introduction and objectives: There is currently increasing interest in epicardial adipose tissue (EAT) as a marker of cardiovascular disease. Our purpose was to describe EAT, measured by transthoracic echocardiography, and to assess its association with metabolic syndrome (MS) in the RIVANA population-based study. Methods: Physical examination was performed in 880 participants aged 45 to 74 years (492 of them with MS according to the harmonized definition). Fasting glucose, high-density lipoprotein cholesterol, triglyceride, and C-reactive protein concentrations were determined in a blood sample. In all participants, EAT thickness was measured with transthoracic echocardiography at end-systole. Results: Among participants without MS, the prevalence of EAT ≥ 5 mm significantly increased with age (OR > 65 years vs 45-54 years = 8.22; 95%CI, 3.90-17.35; P for trend < .001). Increasing EAT quintiles were significantly associated with MS (OR fifth quintile vs first quintile = 3.26; 95%CI, 1.59-6.71; P for trend = .001). Considering the different MS criteria, increasing quintiles of EAT were independently associated with low high-density lipoprotein cholesterol (OR fifth quintile vs first quintile = 2.65; 95%CI, 1.16-6.05; P for trend = .028), high triglycerides (OR fifth quintile vs first quintile = 2.22; 95%CI, 1.26-3.90; P for trend = .003), and elevated waist circumference (OR fifth quintile vs first quintile = 6.85; 95%CI, 2.91-16.11; P for trend < .001). Conclusions: In a subsample of the general population, EAT measured by echocardiography increased significantly and independently with age. Increased EAT thickness was independently associated with MS and with low high-density lipoprotein cholesterol, high triglycerides, and elevated waist circumference as individual criteria (AU)

Epicardial Adipose Tissue in the General Middle-aged Population and Its Association With Metabolic Syndrome.

INTRODUCTION AND OBJECTIVES: There is currently increasing interest in epicardial adipose tissue (EAT) as a marker of cardiovascular disease. Our purpose was to describe EAT, measured by transthoracic echocardiography, and to assess its association with metabolic syndrome (MS) in the RIVANA population-based study. METHODS: Physical examination was performed in 880 participants aged 45 to 74 years (492 of them with MS according to the harmonized definition). Fasting glucose, high-density lipoprotein cholesterol, triglyceride, and C-reactive protein concentrations were determined in a blood sample. In all participants, EAT thickness was measured with transthoracic echocardiography at end-systole. RESULTS: Among participants without MS, the prevalence of EAT ≥ 5mm significantly increased with age (OR > 65 years vs 45-54 years=8.22; 95%CI, 3.90-17.35; P for trend<.001). Increasing EAT quintiles were significantly associated with MS (OR fifth quintile vs first quintile=3.26; 95%CI, 1.59-6.71; P for trend=.001). Considering the different MS criteria, increasing quintiles of EAT were independently associated with low high-density lipoprotein cholesterol (OR fifth quintile vs first quintile=2.65; 95%CI, 1.16-6.05; P for trend=.028), high triglycerides (OR fifth quintile vs first quintile=2.22; 95%CI, 1.26-3.90; P for trend=.003), and elevated waist circumference (OR fifth quintile vs first quintile=6.85; 95%CI, 2.91-16.11; P for trend<.001). CONCLUSIONS: In a subsample of the general population, EAT measured by echocardiography increased significantly and independently with age. Increased EAT thickness was independently associated with MS and with low high-density lipoprotein cholesterol, high triglycerides, and elevated waist circumference as individual criteria.

Risk of Cause-Specific Death in Individuals With Diabetes: A Competing Risks Analysis.

OBJECTIVE: Diabetes is a common cause of shortened life expectancy. We aimed to assess the association between diabetes and cause-specific death. RESEARCH DESIGN AND METHODS: We used the pooled analysis of individual data from 12 Spanish population cohorts with 10-year follow-up. Participants had no previous history of cardiovascular diseases and were 35-79 years old. Diabetes status was self-reported or defined as glycemia >125 mg/dL at baseline. Vital status and causes of death were ascertained by medical records review and linkage with the official death registry. The hazard ratios and cumulative mortality function were assessed with two approaches, with and without competing risks: proportional subdistribution hazard (PSH) and cause-specific hazard (CSH), respectively. Multivariate analyses were fitted for cardiovascular, cancer, and noncardiovascular noncancer deaths. RESULTS: We included 55,292 individuals (15.6% with diabetes and overall mortality of 9.1%). The adjusted hazard ratios showed that diabetes increased mortality risk: 1) cardiovascular death, CSH = 2.03 (95% CI 1.63-2.52) and PSH = 1.99 (1.60-2.49) in men; and CSH = 2.28 (1.75-2.97) and PSH = 2.23 (1.70-2.91) in women; 2) cancer death, CSH = 1.37 (1.13-1.67) and PSH = 1.35 (1.10-1.65) in men; and CSH = 1.68 (1.29-2.20) and PSH = 1.66 (1.25-2.19) in women; and 3) noncardiovascular noncancer death, CSH = 1.53 (1.23-1.91) and PSH = 1.50 (1.20-1.89) in men; and CSH = 1.89 (1.43-2.48) and PSH = 1.84 (1.39-2.45) in women. In all instances, the cumulative mortality function was significantly higher in individuals with diabetes. CONCLUSIONS: Diabetes is associated with premature death from cardiovascular disease, cancer, and noncardiovascular noncancer causes. The use of CSH and PSH provides a comprehensive view of mortality dynamics in a population with diabetes.

On the problem of type 2 diabetes-related mortality in the Canary Islands, Spain. The DARIOS Study.

AIMS: To compare diabetes-related mortality rates and factors associated with this disease in the Canary Islands compared with other 10 Spanish regions. METHODS: In a cross-sectional study of 28,887 participants aged 35-74 years in Spain, data were obtained for diabetes, hypertension, dyslipidemia, obesity, insulin resistance (IR), and metabolic syndrome. Healthcare was measured as awareness, treatment and control of diabetes, dyslipidemia, and hypertension. Standardized mortality rate ratios (SRR) were calculated for the years 1981 to 2011 in the same regions. RESULTS: Diabetes, obesity, and hypertension were more prevalent in people under the age of 64 in the Canary Islands than in Spain. For all ages, metabolic syndrome and insulin resistance (IR) were also more prevalent in those from the Canary Islands. Healthcare parameters were similar in those from the Canary Islands and the rest of Spain. Diabetes-related mortality in the Canary Islands was the highest in Spain since 1981; the maximum SRR was reached in 2011 in men (6.3 versus the region of Madrid; p<0.001) and women (9.5 versus Madrid; p<0.001). Excess mortality was prevalent from the age of 45 years and above. CONCLUSIONS: Diabetes-related mortality is higher in the Canary Islands population than in any other Spanish region. The high mortality and prevalence of IR warrants investigation of the genetic background associated with a higher incidence and poor prognosis for diabetes in this population. The rise in SRR calls for a rapid public health policy response.

Perfil metabólico-inflamatorio en la transición obesidad, síndrome metabólico y diabetes mellitus en población mediterránea. Estudio DARIOS Inflamatorio / Metabolic and inflammatory profiles of biomarkers in obesity, metabolic syndrome, and diabetes in a mediterranean population. Darios inflammatory study

Introducción y objetivos No se ha estudiado en comparación con normopeso el perfil de los biomarcadores relacionados con obesidad, síndrome metabólico y diabetes mellitus. Se pretende caracterizar el perfil de biomarcadores en el continuo de riesgo metabólico definido por la transición de normopeso a obesidad, síndrome metabólico y diabetes mellitus.MétodosAnálisis transversal de datos agrupados procedentes de siete estudios poblacionales españoles. Se determinaron 20 biomarcadores del metabolismo de los hidratos de carbono y los lípidos, inflamatorios, de coagulación, oxidación, hemodinámicos y de lesión miocárdica. Se realizaron modelos de regresión multinomial ajustados para los fenotipos sano, obesidad, síndrome metabólico y diabetes mellitus.ResultadosSe incluyó a 2.851 participantes, con media de edad de 57,4 ± 8,8 años; 1.269 (44,5%) eran varones; 464 sujetos tenían obesidad; 443, síndrome metabólico; 473, diabetes mellitus, y 1.471, normopeso (sujetos sanos). Los biomarcadores que mostraron asociación positiva significativa con al menos uno de los fenotipos clínicos de interés fueron la proteína C reactiva de alta sensibilidad, la apolipoproteína B100, la leptina y la insulina. La apolipoproteina A1 y la adiponectina mostraron asociación negativa.ConclusionesEl grupo de normopeso, y algo menos la obesidad, se diferencian del síndrome metabólico y la diabetes mellitus en su perfil metabólico, inflamatorio y lipídico, lo que indica la relevancia de estos mecanismos en el continuo del riesgo metabólico. Estas diferencias son menores entre el síndrome metabólico y la diabetes mellitus (AU)

Introduction and objectives There is a paucity of data regarding the differences in the biomarker profiles of patients with obesity, metabolic syndrome, and diabetes mellitus as compared to a healthy, normal weight population. We aimed to study the biomarker profile of the metabolic risk continuum defined by the transition from normal weight to obesity, metabolic syndrome, and diabetes mellitus.MethodsWe performed a pooled analysis of data from 7 cross-sectional Spanish population-based surveys. An extensive panel comprising 20 biomarkers related to carbohydrate metabolism, lipids, inflammation, coagulation, oxidation, hemodynamics, and myocardial damage was analyzed. We employed age- and sex-adjusted multinomial logistic regression models for the identification of those biomarkers associated with the metabolic risk continuum phenotypes: obesity, metabolic syndrome, and diabetes mellitus.ResultsA total of 2851 subjects were included for analyses. The mean age was 57.4 (8.8) years, 1269 were men (44.5%), and 464 participants were obese, 443 had metabolic syndrome, 473 had diabetes mellitus, and 1471 had a normal weight (healthy individuals). High-sensitivity C-reactive protein, apolipoprotein B100, leptin, and insulin were positively associated with at least one of the phenotypes of interest. Apolipoprotein A1 and adiponectin were negatively associated.ConclusionsThere are differences between the population with normal weight and that having metabolic syndrome or diabetes with respect to certain biomarkers related to the metabolic, inflammatory, and lipid profiles. The results of this study support the relevance of these mechanisms in the metabolic risk continuum. When metabolic syndrome and diabetes mellitus are compared, these differences are less marked (AU)

Metabolic and inflammatory profiles of biomarkers in obesity, metabolic syndrome, and diabetes in a Mediterranean population. DARIOS Inflammatory study.

INTRODUCTION AND OBJECTIVES: There is a paucity of data regarding the differences in the biomarker profiles of patients with obesity, metabolic syndrome, and diabetes mellitus as compared to a healthy, normal weight population. We aimed to study the biomarker profile of the metabolic risk continuum defined by the transition from normal weight to obesity, metabolic syndrome, and diabetes mellitus. METHODS: We performed a pooled analysis of data from 7 cross-sectional Spanish population-based surveys. An extensive panel comprising 20 biomarkers related to carbohydrate metabolism, lipids, inflammation, coagulation, oxidation, hemodynamics, and myocardial damage was analyzed. We employed age- and sex-adjusted multinomial logistic regression models for the identification of those biomarkers associated with the metabolic risk continuum phenotypes: obesity, metabolic syndrome, and diabetes mellitus. RESULTS: A total of 2851 subjects were included for analyses. The mean age was 57.4 (8.8) years, 1269 were men (44.5%), and 464 participants were obese, 443 had metabolic syndrome, 473 had diabetes mellitus, and 1471 had a normal weight (healthy individuals). High-sensitivity C-reactive protein, apolipoprotein B100, leptin, and insulin were positively associated with at least one of the phenotypes of interest. Apolipoprotein A1 and adiponectin were negatively associated. CONCLUSIONS: There are differences between the population with normal weight and that having metabolic syndrome or diabetes with respect to certain biomarkers related to the metabolic, inflammatory, and lipid profiles. The results of this study support the relevance of these mechanisms in the metabolic risk continuum. When metabolic syndrome and diabetes mellitus are compared, these differences are less marked.

Derivation and validation of a set of 10-year cardiovascular risk predictive functions in Spain: the FRESCO Study.

OBJECTIVE: To derive and validate a set of functions to predict coronary heart disease (CHD) and stroke, and validate the Framingham-REGICOR function. METHOD: Pooled analysis of 11 population-based Spanish cohorts (1992-2005) with 50,408 eligible participants. Baseline smoking, diabetes, systolic blood pressure (SBP), lipid profile, and body mass index were recorded. A ten-year follow-up included re-examinations/telephone contact and cross-linkage with mortality registries. For each sex, two models were fitted for CHD, stroke, and both end-points combined: model A was adjusted for age, smoking, and body mass index and model B for age, smoking, diabetes, SBP, total and HDL cholesterol, and for hypertension treatment by SBP, and age by smoking and by SBP interactions. RESULTS: The 9.3-year median follow-up accumulated 2973 cardiovascular events. The C-statistic improved from model A to model B for CHD (0.66 to 0.71 for men; 0.70 to 0.74 for women) and the combined CHD-stroke end-points (0.68 to 0.71; 0.72 to 0.75, respectively), but not for stroke alone. Framingham-REGICOR had similar C-statistics but overestimated CHD risk. CONCLUSIONS: The new functions accurately estimate 10-year stroke and CHD risk in the adult population of a typical southern European country. The Framingham-REGICOR function provided similar CHD prediction but overestimated risk.

Prevalence of obesity and associated cardiovascular risk: the DARIOS study.

BACKGROUND: To estimate the prevalence of overweight and obesity in the Spanish population as measured with body mass index (BMI), waist circumference (WC) and waist to height ratio (WHtR) and to determine the associated cardiovascular risk factors. METHODS: Pooled analysis with individual data from 11 studies conducted in the first decade of the 21st century. Participants aged 35-74 years were asked about the history of cardiovascular diseases, hypertension, diabetes and hypercholesterolemia. Height, weight, WC, blood pressure, glycaemia, total cholesterol, low-density and high-density lipoprotein cholesterol and coronary risk were measured. The prevalence of overweight (BMI 25-29.9 kg/m(2)), general obesity (BMI ≥ 30 kg/m(2)), suboptimal WC (≥ 80 cm and < 88 in women, ≥ 94 and < 102 in men), abdominal obesity (WC ≥88 cm ≥102 cm in women and men, respectively) and WHtR ≥0.5 was estimated, standardized for the European population. RESULTS: We included 28,743 individuals. The prevalence of overweight and suboptimal WC was 51% and 30% in men and 36% and 22% in women, respectively; general obesity was 28% in both sexes and abdominal obesity 36% in men and 55% in women. The prevalence of WHtR ≥0.5 was 89% and 77% in men and women, respectively. All cardiovascular risk factors were significantly associated with abnormal increased values of BMI, WC and WHtR. Hypertension showed the strongest association with overweight [OR = 1.99 (95% confidence interval 1.81-2.21) and OR = 2.10 (1.91-2.31)]; suboptimal WC [OR = 1.78 (1.60-1.97) and OR = 1.45 (1.26-1.66)], with general obesity [OR = 4.50 (4.02-5.04), and OR = 5.20 (4.70-5.75)] and with WHtR ≥0.5 [OR = 2.94 (2.52-3.43), and OR = 3.02 (2.66-3.42)] in men and women respectively, besides abdominal obesity in men only [OR = 3.51 (3.18-3.88)]. Diabetes showed the strongest association with abdominal obesity in women [OR = 3,86 (3,09-4,89). CONCLUSIONS: The prevalence of obesity in Spain was high. Overweight, suboptimal WC, general, abdominal obesity and WHtR ≥0.5 was significantly associated with diabetes, hypertension, hypercholesterolemia and coronary risk. The use of lower cut-off points for both BMI and particularly WC and could help to better identify the population at risk and therefore achieve more effective preventive measures.

The influence of obesity on the assessment of carotid intima-media thickness.

BACKGROUND: The assessment of carotid intima-media thickness (CIMT) may improve cardiovascular risk prediction. The optimal protocol for CIMT measurement is unclear. CIMT may be measured in the common carotid artery (CCA), carotid bifurcation (CB), and internal carotid artery (ICA), but measurements from CB and ICA are more difficult to obtain. We studied the influence of body mass index (BMI) and atheroma plaques on the capacity to obtain CIMT measurements at different carotid sites. METHODS: Using an automatic system, CIMT was measured in 700 subjects aged 45-75, in the near and far walls of CCA, CB, and ICA bilaterally. The presence of atheroma plaques, BMI and vascular risk factors were recorded. RESULTS: CIMT measurements in CCA were possible in all except one subject. It was not possible to obtain CIMT measurements at CB or ICA in 24.1% of normal weight and 58.8% of obese subjects. The likelihood of obtaining CIMT measurement at all carotid sites decreased as the BMI increased. Atheroma plaques in a carotid segment did not preclude CIMT measurement at this site. CONCLUSIONS: CIMT measurements in distal carotid segments are more challenging in obese subjects. Measuring CIMT at CCA remains feasible in obese subjects and should be the primary endpoint in these subjects. Nevertheless, CB and ICA measurements, when feasible, would improve risk classification.

Tratamiento y control de los factores de riesgo según el riesgo coronario en la población española del estudio DARIOS / Risk factor treatment and control in relation to coronary disease Risk in the spanish population of the DARIOS study

Introducción y objetivos. Tratar y controlar los factores de riesgo cardiovascular es una estrategia fundamental de prevención primaria. El objetivo es analizar la proporción de población de prevención primaria de 35-74 años tratada y controlada, según niveles de riesgo coronario. Métodos. Análisis agrupado con datos individualizados de 11 estudios poblacionales de la primera década del siglo xxi . Se utilizaron cuestionarios estandarizados y medidas de presión arterial, glucohemoglobina y perfil lipídico. Se consideró buen control con presión arterial<140/90mmHg, glucohemoglobina < 7% y en la hipercolesterolemia con dos criterios: Sociedades Europeas y Programa de Actividades Preventivas y Promoción de la Salud. Resultados. Se incluyó a 27.903 participantes (el 54% mujeres). Recibían tratamiento farmacológico el 68 y el 73% de los varones y las mujeres con antecedentes de hipertensión, respectivamente (p<0,001), el 66 y el 69% de los diabéticos (p=0,03) y el 39 y el 42% de los hipercolesterolémicos (p<0,001). Tenían buen control el 34 y el 42% de los varones y las mujeres con hipertensión (p<0,001), el 65 y el 63% de los diabéticos (p=0,626), el 2 y el 3% de los hipercolesterolémicos según Sociedades Europeas (p=0,092) y el 46 y el 52% según Programa de Actividades Preventivas y Promoción de la Salud (p<0,001). La proporción de participantes no controlados aumentó con el riesgo coronario (todos, p<0,001), excepto en los varones diabéticos. Las mujeres con riesgo coronario ≥ 10% recibían más tratamiento hipolipemiante que los varones (el 59 frente al 50%; p<0,024). Conclusiones. La proporción de personas con buen control es del 65% en el mejor de los casos. Los criterios de control de la hipercolesterolemia de las Sociedades Europeas apenas se alcanzan. El tratamiento hipolipemiante no se prioriza en personas de riesgo coronario alto (AU)

Introduction and objectives. The treatment and control of cardiovascular risk factors both play key roles in primary prevention. The aim of the present study is to analyze the proportion of primary prevention patients aged 35-74 years being treated and controlled in relation to their level of coronary risk. Methods. Pooled analysis with individual data from 11 studies conducted in the first decade of the 21st century. We used standardized questionnaires and blood pressure measures, glycohemoglobin and lipid profiles. We defined optimal risk factor control as blood pressure <140/90mmHg and glycohemoglobin <7%. In hypercholesterolemia, we applied both the European Societies and Health Prevention and Promotion Activities Programme criteria. Results. We enrolled 27 903 participants (54% women). Drug treatments were being administered to 68% of men and 73% of women with a history of hypertension (P<.001), 66% and 69% respectively, of patients with diabetes (P=.03), and 39% and 42% respectively, of those with hypercholesterolemia (P<.001). Control was good in 34% of men and 42% of women with hypertension (P<.001); 65% and 63% respectively, of those with diabetes (P=.626); 2% and 3% respectively, of patients with hypercholesterolemia according to European Societies criteria (P=.092) and 46% and 52% respectively, of those with hypercholesterolemia according to Health Prevention and Promotion Activities Programme criteria (P<.001). The proportion of uncontrolled participants increased with coronary risk (P<.001), except in men with diabetes. Lipid-lowering treatments were more often administered to women with ≥10% coronary risk than to men (59% vs. 50%, P<.024). Conclusions. The proportion of well-controlled participants was 65% at best. The European Societies criteria for hypercholesterolemia were vaguely reached. Lipid-lowering treatment is not prioritized in patients at high coronary risk (AU)

[Risk factor treatment and control in relation to coronary disease risk in the Spanish population of the DARIOS Study]. / Tratamiento y control de los factores de riesgo según el riesgo coronario en la población española del estudio DARIOS.

INTRODUCTION AND OBJECTIVES: The treatment and control of cardiovascular risk factors both play key roles in primary prevention. The aim of the present study is to analyze the proportion of primary prevention patients aged 35-74 years being treated and controlled in relation to their level of coronary risk. METHODS: Pooled analysis with individual data from 11 studies conducted in the first decade of the 21st century. We used standardized questionnaires and blood pressure measures, glycohemoglobin and lipid profiles. We defined optimal risk factor control as blood pressure < 140/90 mm Hg and glycohemoglobin <7%. In hypercholesterolemia, we applied both the European Societies and Health Prevention and Promotion Activities Programme criteria. RESULTS: We enrolled 27 903 participants (54% women). Drug treatments were being administered to 68% of men and 73% of women with a history of hypertension (P<.001), 66% and 69% respectively, of patients with diabetes (P=.03), and 39% and 42% respectively, of those with hypercholesterolemia (P<.001). Control was good in 34% of men and 42% of women with hypertension (P<.001); 65% and 63% respectively, of those with diabetes (P=.626); 2% and 3% respectively, of patients with hypercholesterolemia according to European Societies criteria (P=.092) and 46% and 52% respectively, of those with hypercholesterolemia according to Health Prevention and Promotion Activities Programme criteria (P<.001). The proportion of uncontrolled participants increased with coronary risk (P<.001), except in men with diabetes. Lipid-lowering treatments were more often administered to women with ≥ 10% coronary risk than to men (59% vs. 50%, P = 0,024). [corrected] CONCLUSIONS: The proportion of well-controlled participants was 65% at best. The European Societies criteria for hypercholesterolemia were vaguely reached. Lipid-lowering treatment is not prioritized in patients at high coronary risk.

Factores de riesgo cardiovascular en España en la primera década del siglo xxi: análisis agrupado con datos individuales de 11 estudios de base poblacional, estudio DARIOS / Cardiovascular risk factors in Spain in the first decade of the 21st century, a pooled analysis with individual data from 11 population-based studies: the DARIOS study

Introducción y objetivos. Analizar la prevalencia de factores de riesgo cardiovascular en personas de 35-74 años en 10 comunidades autónomas españolas y determinar el grado de variabilidad geográfica en la distribución de los factores de riesgo cardiovascular. Métodos. Análisis agrupado con datos individuales de 11 estudios desarrollados en la primera década del siglo xxi con un promedio de tasa de participación del 73%. Se midió el perfil lipídico (con validación cruzada de laboratorios), glucemia, presión arterial, perímetro de la cintura, peso y talla y se administraron cuestionarios estandarizados. Se estimó la prevalencia estandarizada a la población europea de tabaquismo, diabetes, hipertensión arterial, dislipemia y obesidad. Además, se estimó el coeficiente de variación entre estudios componentes en la prevalencia de cada factor de riesgo. Resultados. Se incluyó a 28.887 participantes. Los factores de riesgo cardiovascular más prevalentes fueron: hipertensión arterial (el 47% en varones y el 39% en mujeres), dislipemia con colesterol total >= 250 mg/dl (el 43 y el 40%), obesidad (el 29% en ambos sexos), tabaquismo (el 33 y el 21%) y diabetes mellitus (el 16 y el 11%). El colesterol total >= 190 y >= 250 mg/dl presentó el coeficiente de variación mínimo y máximo, respectivamente (el 7-24% en varones y el 7-26% en mujeres). La concordancia media en las determinaciones lipídicas entre laboratorios fue excelente. Conclusiones. La prevalencia de hipertensión arterial, dislipemia, obesidad, tabaquismo y diabetes mellitus, es elevada, con variabilidad relativamente baja en la población de 35 a 74 años entre comunidades autónomas. Canarias, Extremadura y Andalucía presentan mayor número de factores de riesgo cardiovascular significativamente más prevalentes que el promedio de los 11 estudios componentes (AU)

Introduction and objectives. To estimate the prevalence of cardiovascular risk factors in individuals aged 35-74 years in 10 of Spain's autonomous communities and determine the geographic variation of cardiovascular risk factors distribution. Methods. Pooled analysis with individual data from 11 studies conducted in the first decade of the 21st century. The average response rate was 73%. Lipid profile (with laboratory cross-validation), glucose level, blood pressure, waist circumference, height, and weight were measured and standard questionnaires administered. Age-standardized prevalence of smoking, diabetes, hypertension, dyslipidemia, and obesity in the European population were calculated. Furthermore, the coefficient of variation between component studies was determined for the prevalence of each risk factor. Results. In total, 28,887 participants were included. The most prevalent cardiovascular risk factors were high blood pressure (47% in men, 39% in women), total cholesterol >=250mg/dL (43% and 40%, respectively), obesity (29% and 29%, respectively), tobacco use (33% and 21%, respectively), and diabetes (16% and 11%, respectively). Total cholesterol >=190 and >=250mg/dL were the respective minimum and maximum coefficients of variation (7%-24% in men, 7%-26% in women). Average concordance in lipid measurements between laboratories was excellent. Conclusions. Prevalence of high blood pressure, dyslipidemia, obesity, tobacco use and diabetes is high. Little variation was observed between autonomous communities in the population aged 35-74 years. However, presence of the most prevalent cardiovascular risk factors in the Canary Islands, Extremadura and Andalusia was greater than the mean of the 11 studies (AU)

[Cardiovascular risk factors in Spain in the first decade of the 21st Century, a pooled analysis with individual data from 11 population-based studies: the DARIOS study]. / Factores de riesgo cardiovascular en España en la primera década del siglo xxi: análisis agrupado con datos individuales de 11 estudios de base poblacional, estudio DARIOS.

INTRODUCTION AND OBJECTIVES: To estimate the prevalence of cardiovascular risk factors in individuals aged 35-74 years in 10 of Spain's autonomous communities and determine the geographic variation of cardiovascular risk factors distribution. METHODS: Pooled analysis with individual data from 11 studies conducted in the first decade of the 21st century. The average response rate was 73%. Lipid profile (with laboratory cross-validation), glucose level, blood pressure, waist circumference, height, and weight were measured and standard questionnaires administered. Age-standardized prevalence of smoking, diabetes, hypertension, dyslipidemia, and obesity in the European population were calculated. Furthermore, the coefficient of variation between component studies was determined for the prevalence of each risk factor. RESULTS: In total, 28,887 participants were included. The most prevalent cardiovascular risk factors were high blood pressure (47% in men, 39% in women), total cholesterol ≥ 250 mg/dL (43% and 40%, respectively), obesity (29% and 29%, respectively), tobacco use (33% and 21%, respectively), and diabetes (16% and 11%, respectively). Total cholesterol ≥ 190 and ≥ 250 mg/dL were the respective minimum and maximum coefficients of variation (7%-24% in men, 7%-26% in women). Average concordance in lipid measurements between laboratories was excellent. CONCLUSIONS: Prevalence of high blood pressure, dyslipidemia, obesity, tobacco use and diabetes is high. Little variation was observed between autonomous communities in the population aged 35-74 years. However, presence of the most prevalent cardiovascular risk factors in the Canary Islands, Extremadura and Andalusia was greater than the mean of the 11 studies.

Adaptation of the Framingham-Wilson coronary risk equation for the population of Navarra (RICORNA).

INTRODUCTION AND OBJECTIVES: The Framingham equations overestimate the risk of coronary disease in populations with a low disease incidence. It is more appropriate to take the local population's characteristics into account when estimating coronary risk. Accordingly, the Framingham-Wilson equation has been adapted for the population of Navarra, Spain. This article presents 10-year overall coronary risk charts. METHODS: The Framingham-Wilson equation was adapted using data on the prevalence of cardiovascular risk factors and the coronary event rate in the population of Navarra. The version of the Framingham-Wilson equation used included high-density lipoprotein cholesterol (HDL-C). The probability of an event at 10 years for different combinations of risk factors, with an HDL-C concentration of 35-59 mg/dL, are illustrated. RESULTS: Using the Framingham equation adapted for Navarra (i.e., the RICORNA or Riesgo Coronario Navarra), the proportion with an estimated probability of a coronary event in the next 10 years greater than 9% is approximately half that in the original Framingham population, and the proportion with a high or very high probability (i.e., 20%) is one-third. An HDL-C level <35 mg/dL increases the risk by 50% and a level > or =60 mg/dL reduces it by 50%, approximately. The average HDL-C level observed in the population was 63.9 mg/dL overall, and 70.1 mg/dL in women. CONCLUSIONS: The RICORNA equation can provide a more precise estimate of overall coronary risk and could be useful in primary disease prevention in Navarra. The high HDL-C concentration observed in Navarra might contribute to the associated low coronary morbidity and mortality.

Adaptación de la función de riesgo coronario de Framingham-Wilson para la población de Navarra (RICORNA) / Adaptation of the Framingham-Wilson coronary risk equation for the population of Navarra (RICORNA)

Introducción y objetivos. Las funciones de Framingham sobrestiman el riesgo de enfermedad coronaria en poblaciones con baja incidencia. Es más apropiado estimar el riesgo coronario considerando las características poblacionales locales. En este sentido, se ha adaptado la ecuación de Framingham-Wilson para la población de Navarra. Se presentan las tablas de riesgo coronario global a 10 años. Métodos. Se ha adaptado la ecuación de Framingham-Wilson mediante los datos de prevalencia de los factores de riesgo cardiovascular y la tasa de acontecimientos coronarios de Navarra. Se ha utilizado la ecuación de Framingham-Wilson que incluye el colesterol unido a lipoproteínas de alta densidad (cHDL). Se muestran las probabilidades de acontecimientos a 10 años correspondientes a las distintas combinaciones de los factores de riesgo, para una concentración de cHDL de 35-59 mg/dl. Resultados. En la función adaptada Framingham-Navarra (RICORNA), la proporción de estimaciones de probabilidad de acontecimiento coronario a 10 años superior al 9% es aproximadamente 2 veces menor, y la de riesgo alto o muy alto (≥ 20%) es 3 veces menor que en las originales de Framingham. Los valores de cHDL < 35 mg/dl incrementan el riesgo un 50% y los valores ≥ 60 mg/dl lo reducen un 50%, aproximadamente. El cHDL observado tuvo un valor medio poblacional de 63,9 mg/dl y de 70,1 mg/dl en las mujeres. Conclusiones. La función RICORNA es una herramienta que puede ser utilizada para estimar con más precisión el riesgo coronario global en la prevención primaria de esta enfermedad en Navarra. La elevada concentración de cHDL observada en Navarra puede contribuir a su baja morbimortalidad coronaria (AU)

Introduction and objectives. The Framingham equations overestimate the risk of coronary disease in populations with a low disease incidence. It is more appropriate to take the local population’s characteristics into account when estimating coronary risk. Accordingly, the Framingham-Wilson equation has been adapted for the population of Navarra, Spain. This article presents 10-year overall coronary risk charts. Methods. The Framingham–Wilson equation was adapted using data on the prevalence of cardiovascular risk factors and the coronary event rate in the population of Navarra. The version of the Framingham-Wilson equation used included high-density lipoprotein cholesterol (HDL-C). The probability of an event at 10 years for different combinations of risk factors, with an HDL-C concentration of 35-59 mg/dL, are illustrated. Results. Using the Framingham equation adapted for Navarra (ie, the RICORNA or Riesgo Coronario Navarra), the proportion with an estimated probability of a coronary event in the next 10 years greater than 9% is approximately half that in the original Framingham population, and the proportion with a high or very high probability (ie, 20%) is one-third. An HDL-C level <35 mg dl increases the risk by 50 and a level 8805 60 reduces it approximately average hdl-c observed in population was 63 9 overall 70 1 women conclusions ricorna equation can provide more precise estimate of coronary could be useful primary disease prevention navarra high concentration might contribute to associated low morbidity mortality (AU)